TherapeuticsMD, Inc. Stock Split Ratio
TherapeuticsMD, Inc. (TXMD) reported Stock Split Ratio of 2.00% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-04-07.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-11-14
- TherapeuticsMD, Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2022-03-31 was 2.00%.
- TherapeuticsMD, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2022 was 2.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | 2.00% 10-K · filed 2023-04-07 | ||||
| 2022-09-30 | 2.00% 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | 2.00% 10-Q · filed 2022-08-15 | ||||
| 2022-05-06 | 2.00% 10-Q · filed 2023-11-14 | ||||
| 2022-03-31 | 2.00% 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |